HCPCS Level II code J9359 denotes injection of loncastuximab tesirine-lpyl, charged per 0.075 mg unit. The code identifies administration of a targeted antibody‑drug conjugate used in oncology care and is integral to billing for outpatient chemotherapy services. Nationally, accurate use of this HCPCS Level II code supports consistent drug utilization reporting, claims processing, and reimbursement for high-cost specialty medications.

Key payers covered in this overview include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise explanation of the clinical and service context for J9359, typical sites of service, and the common modifiers associated with oncology drug administration. The content highlights what to expect for claims submissions and payer interactions without prescribing clinical or billing actions.

This publication outlines benchmark considerations and policy-relevant topics such as unit-based drug billing, site-of-service implications for outpatient infusion, and Medicare coverage relevance. Data elements not provided in the input—such as specific ICD-10 pairings, associated taxonomies, or payer-specific rate benchmarks—are noted as unavailable. The piece equips revenue cycle and clinical administrative teams with the code context needed for operational and policy discussions at a national level.